Cue Biopharma, Inc.

NASDAQ:CUE

Biotechnology

Healthcare
$14.10 +1.42%

+$0.38 today

Market cap
$102.43M
Beta
2.53
P/E (TTM)
-6.7
EPS (TTM)
-$4.06
52W Low $4.98High $41.42

Volume 0.21M

Average 0.74M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$21.69M

FY 2025 · Annual

Investing Cash Flow

$75,000.00

FY 2025 · Annual

+134.4% YoY

Financing Cash Flow

$26.29M

FY 2025 · Annual

+156.7% YoY

Cash Flow Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Net Income(44.16M)(53.01M)(50.73M)(40.67M)(26.6M)
Depreciation & Amortization(1.78M)1.81M3.44M2.35M958K
Deferred Income Tax00000
Stock-Based Compensation11.52M9.5M8.18M6.85M4.74M
Change in Working Capital(4.39M)356K(934K)(4.93M)(3.3M)
Accounts Receivables(1.73M)3.09M(1.64M)753K(6.5M)
Inventory00000
Accounts Payables520.4K83K770K(678K)1.13M
Other Working Capital(3.18M)(2.81M)(63K)(5M)2.08M
Other Non-Cash Items(26.13K)(454K)90K74K2.51M
Operating Cash Flow(38.84M)(41.81M)(39.96M)(36.33M)(21.69M)
Capital Expenditures(913.04K)(171K)0(66K)(177K)
Acquisitions (Net)000040K
Purchases of Investments0(29.45M)00(16.5M)
Sales of Investments10M5M25M016.5M
Other Investing Activities21.55K6K2K98K212K
Investing Cash Flow9.11M(24.61M)25M32K75K
Debt Repayment010M(2M)(4M)(4.5M)
Common Stock Issued17.38M39.3M13.39M14.22M30.79M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.85M4.36M473K18K0
Financing Cash Flow19.23M53.66M11.86M10.24M26.29M
Effect of Forex Changes00000
Net Change in Cash(10.5M)(12.76M)(3.1M)(26.05M)4.68M
Free Cash Flow(39.75M)(41.98M)(39.96M)(36.4M)(21.86M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$26.6M
+ D&A$958.0K
+ Stock-Based Comp$4.7M
+ Deferred Tax$0
- Working Capital-$3.3M
+ Other Non-Cash$2.5M
= Operating Cash Flow-$21.7M
- Capex-$177.0K
= Free Cash Flow-$21.9M

Analysis

FY2025 free cash flow is -$21.9M. FCF conversion is 82.2% of net income. Operating cash flow was -$21.7M, with capex of -$177.0K. The largest bridge item is Stock-Based Comp at $4.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 10, 2026
4Statement of changes in beneficial ownershipOct 14, 2026
4Statement of changes in beneficial ownershipOct 14, 2026
4Statement of changes in beneficial ownershipOct 14, 2026
SC 13G/ASC 13G/A filingOct 8, 2026

Does CUE generate free cash flow?

Cue Biopharma, Inc. (CUE) generated -$21.86M of free cash flow in fiscal 2025.

How much operating cash flow does CUE produce?

Operating cash flow was -$21.69M, before capital expenditures of $177,000.00.